Antibody-based immune-oncology (IO) has revolutionized the treatment of many cancer types, however not all patients respond, and resistance develops. Accordingly, new strategies are constantly being tested, and as available therapies multiply there is a growing demand to understand how to apply and combine them before clinical implementation.
The objective of the postdoctoral project is to optimize a more physiologically relevant mouse model for future preclinical testing in the context of IO and autoimmune diseases. The project aims to establish second-generation humanized mouse models with well-defined subsets of immune cells that can induce antigen-specific tumor immunity and match the antibody-based therapeutics under development.
The candidate needs to have experimental expertise with mouse models, preferentially humanized mouse models. The candidate needs strong attention to detail and the ability to work in a team-oriented culture where knowledge sharing and idea generation with peers is key for advancing next generation antibody therapeutics.
The candidate will have the opportunity to lead key activities, including some of the following:
- Be responsible scientist for the establishment of multiple next-generation CD34-humanized models.
- Work effectively and goal-oriented in a multidisciplinary environment
- Communicating results in a clear and effective manner to colleagues and management
- Coordinating activities within a focus group
- Be part of a growing community of experts in animal models and antibody therapeutics for the benefit of patients
- A Ph.D. degree in immunology or other related biological science
- Expertise of in vivo models within immuno-oncology, e.g. human immune mouse models, human and murine tumor models
- Hands-on experience with techniques for functional characterization of immune cells, using flow cytometry and cytokine profiling
- Detail-oriented with proven ability to troubleshoot complex problems involving multiple variables
- Ability to critically and independently evaluate data
- Excellent oral and written communication skills demonstrated in public presentations and publications
- Candidate with prior experience of CD34-humanized mouse models
- Competitive salary based on qualifications, and flexible working hours
- Strong cross functional teamwork, room for individual performance and development, and passionate, inspiring, and fun colleagues
Working in Symphogen
Being part of Symphogen, you will always have a challenging job in a creative, goal-oriented, and value-based environment with a meaningful mission – to advance superior mAb therapeutics to improve the lives of patients. You will be a part of a highly engaged and inspiring organization with focus on diversity, teamwork, commitment – and on you as a person. You will be offered good development opportunities and a relevant benefit package.
Domicile: Ballerup, Copenhagen
This is a 3-year temporary position.
For more information you are welcome to contact Team Manager of In Vivo Pharmacology by phone: +45 8838 2536; or e-mail: firstname.lastname@example.org. Or HR-Manager at +45 4526 5050. Please also see www.symphogen.com for information about our company.
If you are interested in the position, please mark your application and CV “In vivo Post Doc” and send it by mail to: email@example.com no later than Dec 10th, 2022. Potential candidates will be invited for interview as they apply, and we reserve the right to terminate before the posting expires.
Symphogen is a subsidiary of Servier and antibody center of excellence primarily focused on oncology and immune oncology. We have a highly efficient antibody discovery and research platform supported by comprehensive early development capabilities.
Our antibody platform delivers antibodies with unique functionalities providing best or first in class potential as combination or mono therapy. Our approach and capabilities are well suited for combination therapies at the core of future cancer treatment.
Symphogen is located in Ballerup in the greater Copenhagen area. The company currently employs approximately 120 people